Table 3 Enrichr-based Gene Ontology (GO) enrichment analysis of genes significantly increased or decreased in expression in peripheral blood mononuclear cells of patients with different clinical subtypes of late AMD. Listed are the three strongest in each category (ranked using the Enrichr computed combined score (CS) which multiplies log p-value to z-score; only CS > 5 were considered to only consider strong signals) within the three GO-terms: Biological Process (BP), Molecular Function (MF), and Cellular Component (CC)
Increased | Decreased | ||||
|---|---|---|---|---|---|
GO | Description | CS | GO | Description | CS |
Patients with GA vs. Healthy controls | |||||
 BP | response to interferon-alpha | 15.10 | BP | positive regulation of memory T cell differentiation | 14.05 |
 BP | positive regulation of autophagy of mitochondrion | 13.71 | BP | regulation of memory T cell differentiation | 13.18 |
 BP | type I interferon signaling pathway | 13.08 | BP | positive regulation of T-helper 2 cell differentiation | 13.16 |
 MF | urea transmembrane transporter activity | 15.87 | MF | NADPH binding | 12.91 |
 MF | acetylcholine receptor regulator activity | 15.48 | MF | G-protein coupled nucleotide receptor activity | 12.90 |
 MF | amide transmembrane transporter activity | 12.40 | MF | G-protein coupled purinergic nucleotide receptor activity | 12.70 |
 CC | T cell receptor complex | 10.27 | CC | – | – |
 CC | Cul4-RING E3 ubiquitin ligase complex | 6.62 | CC | – | – |
 CC | – | – | CC | – | – |
Patients with nAMD vs. Healthy controls | |||||
 BP | oxygen gas homeostasis | 21.30 | BP | lymphocyte activation involved in immune response | 10.65 |
 BP | gas homeostasis | 18.33 | BP | T cell activation involved in immune response | 8.71 |
 BP | regulation of cellular carbohydrate catabolic process | 17.35 | BP | – | – |
 MF | urea transmembrane transporter activity | 15.36 | MF | peptidase activity, acting on L-amino acid peptides | 5.27 |
 MF | iron ion transmembrane transporter activity | 15.27 | MF | – | – |
 MF | sodium:bicarbonate symporter activity | 13.78 | MF | – | – |
 CC | specific granule lumen | 26.32 | CC | – | – |
 CC | tertiary granule lumen | 25.98 | CC | – | – |
 CC | endocytic vesicle lumen | 20.12 | CC | – | – |
Patients with PCV vs. Healthy controls | |||||
 BP | regulator of immune effector process | 18.39 | BP | negative regulation of acute inflammatory response | 13.62 |
 BP | positive regulation of toll-like receptor 4 signaling pathway | 18.14 | BP | positive regulation of T-helper 2 cell differentiation | 13.62 |
 BP | negative regulation by host of viral process | 15.92 | BP | regulation of T-helper 2 cell cytokine production | 12.56 |
 MF | urea transmembrane transporter activity | 18.92 | MF | vascular endothelial growth factor-activated receptor activity | 13.97 |
 MF | amide transmembrane transporter activity | 14.94 | MF | MAP kinase kinase kinase activity | 11.30 |
 MF | signal recognition particle binding | 13.89 | MF | transmembrane receptor protein tyrosine kinase activity | 9.35 |
 CC | endocytic vesicle lumen | 11.94 | CC | NLRP3 inflammasome complex | 9.85 |
 CC | specific granule lumen | 6.87 | CC | nuclear euchromatin | 9.33 |
 CC | tertiary granule lumen | 6.77 | CC | euchromatin | 8.98 |